Triple Negative Breast Cancer FDA Approvals, Emerging Therapies, Pipeline Insights and Companies
Discover the latest drugs and treatment options in the Triple Negative Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Triple Negative Breast Cancer Pipeline Outlook
Key Takeaways from the Triple Negative Breast Cancer Pipeline Report
In January 2025:- Merck Sharp & Dohme LLC- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).
In January 2025:- AstraZeneca:- This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.
In January 2025: Mabwell (Shanghai) Bioscience Co., Ltd.- This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
DelveInsight's Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs
Triple Negative Breast Cancer Emerging Drugs Profile
Camrelizumab: Jiangsu HengRui Medicine
Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin's lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.
SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB264 is an innovative TROP2-directed ADC which was developed by OptiDC, a well-known international ADC R&D platform of Kelun-Biotech, using a proprietary payload-linker strategy (Kthiol design strategy) that achieves an optimized balance of ADC safety and efficacy by combining novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules with a DAR of 7.4 (novel topoisomerase I inhibitors). SKB264 has received Breakthrough Therapy Designations (BTDs) from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic triple-negative breast cancer.
AK117: Akeso Biopharma
AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.
PLX038: ProLynx
PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC. Top1 inhibitors cause DNA breaks and kill tumors that are unable to repair the damage. Previously, Curie researchers showed that about one-third of TNBC patients have defects in DNA damage repair, and should respond to an effective SN-38-based therapy (Coussy et al., 2020). In PLX038, SN-38 is covalently bound to a circulating nanoparticle and is slowly released to provide free SN-38 with a long half-life, low Cmax, and high exposure – important facets for optimal safety and efficacy. Importantly, in preclinical studies PLX038 was shown to accumulate and be retained in solid tumors, where it slowly releases its SN-38. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.
PMD-026: Phoenix Molecular Designs
PhoenixMD's lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data. PFS in women with TNBC is three times longer for patients that express high levels of RSK2 activation as compared to those with low RSK2 activation. Preclinical data shows PMD-026 has the potential to be a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitization for a wide range of refractory cancers in the future. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.
Triple Negative Breast Cancer Companies
Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Triple Negative Breast Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers
Scope of the Triple Negative Breast Cancer Pipeline Report
Coverage- Global
Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Triple Negative Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Triple Negative Breast Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Camrelizumab: Jiangsu HengRui Medicine
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK117: Akeso Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PMD-026: Phoenix Molecular Designs
Drug profiles in the detailed report…..
Inactive Products
Triple Negative Breast Cancer Key Companies
Triple Negative Breast Cancer Key Products
Triple Negative Breast Cancer- Unmet Needs
Triple Negative Breast Cancer- Market Drivers and Barriers
Triple Negative Breast Cancer- Future Perspectives and Conclusion
Triple Negative Breast Cancer Analyst Views
Triple Negative Breast Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dyspepsia-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
38 minutes ago
- Cision Canada
Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio
BASEL, Switzerland, July 14, 2025 /CNW/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients from natural sources, is expanding its texturants offering with the launch of TayaGel ® LA, a new low-acyl gellan gum. The new product will debut at IFT FIRST 2025 in Chicago, marking an important milestone in the company's continued investment in innovation, application expertise and label-friendly ingredient solutions. Developed in response to increasing demand for plant-based and label-friendly formulations, TayaGel ® LA delivers outstanding suspension performance and strong gels at very low use levels. It creates a smooth mouthfeel and has a clear appearance, ideal for applications where clean taste and visual appearance matter. "With TayaGel ® LA, we're expanding the possibilities for formulators seeking reliable, high performing, naturally derived texturant solutions," said Jens Birrer, VP Texturants at Jungbunzlauer. "Our expert team works side by side with customers to ensure the desired texture is achieved when integrating or switching texturants or combining with our other products such as TayaGel ® HA." TayaGel ® LA enhances Jungbunzlauer's texturants portfolio, which now includes: A full range of xanthan gum grades Both high-acyl (HA) and low-acyl (LA) gellan gums Customised blends and application support for superior suspension, gel formation, and more Birrer added, "Produced with the same reliability, expertise and high-quality that define Jungbunzlauer's wider product portfolio, including acidulants, sweeteners and mineral salts, these texturant offerings enable us to support customers across a wide variety of food, beverage and nutrition applications with more consistent results." As part of its ongoing commitment to customer-driven innovation, Jungbunzlauer has continued to strengthen its texturants platform through targeted investments in expertise, capacity and product development. This includes acquisition of AGI in 2024; the addition of senior specialists to its texturants team; and the company's expansion of its biogum capacity from its Port Colborne, Canada site. These developments reflect the company's long-term strategic commitment to supporting customers with deeper know-how, broader functionality, and tailored solutions as they navigate increasingly complex formulation challenges. Visit Jungbunzlauer at Booth #S723 to sample recipes featuring TayaGel ® LA including a vegan panna cotta, fruit purée and more. Jungbunzlauer's experts will be on hand to discuss application needs and formulation challenges. About Jungbunzlauer Jungbunzlauer is a leading producer of high-quality, sustainable ingredients from natural sources, serving industries from food and beverage, to nutrition, health, home and personal care, among others. Leading the way in developing naturally better ingredients that enhance everyday life, we are a trusted partner offering a diverse portfolio of texturants, acidulants, sweeteners, minerals, and tailored solutions to meet our customers' evolving needs. Headquartered in Basel, Switzerland, with state-of-the-art facilities including large-scale fermentation operations across Europe and North America, we proudly serve more than 130 countries worldwide. Founded more than 150 years ago, Jungbunzlauer has grown into a CHF 1.3 billion company, driven by nearly 1,400 dedicated colleagues committed to a healthier, more sustainable future. Learn more at
Cision Canada
4 days ago
- Cision Canada
GoSecure Partners with Northbridge Financial to Provide Incident Preparation and Response Services Français
MONTREAL, July 10, 2025 /CNW/ - GoSecure, a leader in managed cybersecurity and professional cybersecurity services, is pleased to announce a strategic partnership with Northbridge Financial Corporation, a commercial insurance leader and cyber insurance provider in Canada. GoSecure will serve the commercial customers of Northbridge's insurance brands, Northbridge Insurance and Federated Insurance. Northbridge and Federated's commercial Cyber policyholders will gain direct access to GoSecure's dedicated 24/7 incident response helpline, expert consultation, and proactive tools to help prevent and manage cyber incidents. "This partnership marks a major step forward in bringing world-class cybersecurity support to businesses of all sizes," said Neal Creighton, CEO of GoSecure. "By serving as Northbridge customer's first call for cyber incidents, we are reinforcing our commitment to proactive threat defense and rapid response. We look forward to delivering the highest level of protection to their Cyber policyholders." This agreement is just the beginning of GoSecure's expansion into the cyber insurance sector. In addition to providing immediate support to Northbridge and Federated's commercial customers during a cyber incident, eligible policyholders will benefit from proactive services such as cybersecurity self-assessments, vulnerability scans, and follow-up consultations. Qualifying customers may also access cyber incident simulation (tabletop exercises) designed to test response readiness and strengthen incident preparedness. "As cyber threats continue to escalate, businesses need a trusted partner who can help them navigate incidents in real time," said Scott Vandenberg, Vice-President, Corporate Research and Development, at Northbridge. "At Northbridge, it's important to us that our customers are offered proactive support to help prevent cyber incidents from happening, as well as access to immediate, expert-driven guidance to mitigate damage, contain threats, and recover quickly." For more information about GoSecure solutions, visit GoSecure is a recognized cybersecurity leader offering advanced Managed Extended Detection and Response (MXDR) and expert professional services. GoSecure Titan ® managed security solutions deliver multi-vector protection with industry-leading response times across networks, endpoints, and inboxes. For over 20 years, GoSecure has helped organizations close security gaps, reduce risk, and strengthen their overall posture. About Northbridge Financial Corporation: Northbridge Financial Corporation is a leading commercial property and casualty insurance company that has helped protect Canadian businesses for more than 100 years. We offer a wide range of innovative solutions to Canadian businesses through our Northbridge Insurance, Federated Insurance, and TruShield Insurance brands. We are proud to be a 100% Canadian company, wholly-owned by Fairfax Financial Holdings. Visit us at to learn more.
Cision Canada
4 days ago
- Cision Canada
Micrologic recognized as a Representative Vendor on the 2025 Gartner® Market Guide for Digital Sovereignty Solutions Français
QUEBEC CITY, July 10, 2025 /CNW/ - Micrologic, a 100% Canadian-owned company who has built a sovereign cloud, is proud to announce that Gartner has recognized Micrologic as a Representative Vendor on the 2025 Gartner® Market Guide for Digital Sovereignty Solutions. We believe that this acknowledgment underscores Micrologic's commitment to providing secure, true sovereign cloud solutions that meet the highest standards of data sovereignty. As digital sovereignty becomes increasingly critical for organizations in the current geopolitical context, Micrologic continues to lead the way in delivering trusted and compliant cloud services tailored to the unique needs of large public and private organizations in the country. "As a leader in digital sovereignty solutions in Canada, we are excited to be acknowledged by Gartner. This recognition reflects our unwavering dedication to providing large public and private organizations with secure, sovereign cloud infrastructure that empowers them to innovate and grow with confidence. As the only Canadian provider in this category, we are proud to support the digital transformation of businesses across Canada while ensuring their data is subject exclusively to Canadian laws ‒ a major advantage in the face of growing threats of foreign interference", said Stephane Garneau, President & CEO of Micrologic. Gartner, Market Guide for Digital Sovereignty Solutions, By Dennis Smith, Rene Buest, Alessandro Galimberti, 5 May 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Micrologic Micrologic is a Canadian company that has been driving the digital transformation large private and public organizations for over 40 years. They have developed a Canadian sovereign cloud, which is powered by sustainable energy and is equipped with strict certifications. With a pan-Canadian expansion plan involving $150 million in investments, the company has increased its revenue tenfold over the past decade, generating over $1.5 billion in revenue. The company's president, Stéphane Garneau, has been recognized as CEO of the Year by Les Affaires and the Association québécoise des technologies, and was a finalist in the EY Entrepreneur of the Year Award.
